Stockscreener 앱 받기
88.43
3.74%
3.19
시간 외 거래:
89.00
0.57
+0.64%
전일 마감가:
$85.24
열려 있는:
$85.37
하루 거래량:
1.22M
Relative Volume:
1.28
시가총액:
$6.67B
수익:
-
순이익/손실:
$-274.62M
주가수익비율:
-20.43
EPS:
-4.3278
순현금흐름:
$-235.37M
1주 성능:
+6.90%
1개월 성능:
+8.98%
6개월 성능:
+17.13%
1년 성능:
+112.27%
1일 변동 폭
$84.86
$90.53
1주일 범위
$82.72
$91.24
52주 변동 폭
$34.34
$95.31
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
88.43 | 6.50B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Hold |
| 2026-01-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | 개시 | Wolfe Research | Peer Perform |
| 2025-12-17 | 개시 | Stephens | Overweight |
| 2025-12-10 | 개시 | Deutsche Bank | Buy |
| 2025-11-03 | 개시 | Craig Hallum | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-07 | 재확인 | BTIG Research | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-11-25 | 개시 | Canaccord Genuity | Buy |
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Apogee Therapeutics CEO Michael Henderson sells $1.67m in stock By Investing.com - Investing.com India
Apogee Therapeutics CEO Michael Henderson sells $1.67m in stock - Investing.com
Apogee Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com Nigeria
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (APGE) CEO sells 20,000 shares in planned trades, keeps over 1.09M - Stock Titan
Apogee Therapeutics (NASDAQ: APGE) investors back board, pay and auditor - Stock Titan
APGE Stock Price, Quote & Chart - ChartMill
Apogee Therapeutics (APGE) links 7,657-share option grant to director - Stock Titan
Apogee Therapeutics (APGE) director receives stock options for 7,657 shares - Stock Titan
Apogee Therapeutics (APGE) director Lisa Bollinger granted 7,657 stock options - Stock Titan
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Shah Nimish P - Moomoo
Goldman Sachs Maintains Apogee Therapeutics(APGE.US) With Hold Rating, Maintains Target Price $89 - Moomoo
Apogee Therapeutics maps phase 3 push for Zumilokibart, backed by Blackstone funding - MSN
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding - Yahoo Finance
APGE News | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
These 10 mid-cap US healthcare companies carry the market's most expensive valuations - MSN
TD Asset Management Inc Has $9.76 Million Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Why Apogee Therapeutics (APGE) Is Up 8.0% After Phase 2 Win And $1.3 Billion Blackstone Deal - Sahm
Behavioral Patterns of APGE and Institutional Flows - Stock Traders Daily
APGE Maintained by RBC Capital -- Price Target Raised to $97.00 - GuruFocus
RBC Capital raises Apogee Therapeutics stock price target to $97 By Investing.com - Investing.com Australia
RBC Raises Price Target on Apogee Therapeutics to $97 From $82, Keeps Sector Perform, Speculative Risk - marketscreener.com
RBC Capital raises Apogee Therapeutics stock price target to $97 - Investing.com
Apogee Therapeutics CMO Dambkowski sells $432,904 in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $432,904 in stock - Investing.com
Apogee Therapeutics (APGE) CMO trades stock under Rule 10b5-1 plan - Stock Titan
Blackstone pledges $1.3 billion to help develop Apogee skin drug - MSN
Apogee (APGE) Secures Up to $1.3B in Non-Dilutive Financing from Blackstone to Advance Zumilokibart - Insider Monkey
Should Positive Phase 2 Zumilokibart Data and Blackstone Funding Reshape the Outlook for Apogee Therapeutics (APGE) Investors? - Sahm
Apogee Therapeutics readies Zumi for phase 3 with Blackstone backing - MSN
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing - sharewise.com
APGE: Strong phase II-B results and a $1.3B Blackstone deal drive late-stage and combo program expansion - TradingView
Deutsche Bank Adjusts PT on Apogee Therapeutics to $116 From $118, Maintains Buy Rating - marketscreener.com
Apogee Therapeutics (APGE) Among Most Expensive U.S. Healthcare Stocks by Valuation - GuruFocus
These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart - Yahoo Finance
Apogee Therapeutics shares surge following $1.3 billion Blackstone financing partnership (APOG) - MSN
Latham & Watkins Advises Apogee Therapeutics in US$1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences, One of the Largest Life Sciences Financings of 2026 - Legal Desire
Apogee falls following Phase 2 results for zumilokibart in atopic dermatitis - MSN
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
A Quick Look at Today's Ratings for Apogee Therapeutics(APGE.US), With a Forecast Between $81 to $131 - Moomoo
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart - WebWire
Analysts Offer Insights on Healthcare Companies: Agilent (A), Apogee Therapeutics (APGE) and Pfizer (PFE) - The Globe and Mail
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Apogee Therapeutics Inc 주식 (APGE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Jun 03 '26 |
Option Exercise |
22.86 |
4,125 |
94,298 |
211,148 |
| Dambkowski Carl | Chief Medical Officer |
Jun 03 '26 |
Sale |
78.71 |
5,500 |
432,905 |
205,648 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer |
May 13 '26 |
Sale |
82.09 |
20,000 |
1,641,711 |
1,115,987 |
2.60%
0.94%
자본화:
|
볼륨(24시간):